Cerebrovascular Mechanisms of PFAS
Stroke — particularly ischemic stroke from cerebral artery occlusion — shares risk factors with coronary artery disease: hypertension, dyslipidemia, diabetes, and endothelial dysfunction. PFAS contribute to all of these risk factors simultaneously: raising LDL cholesterol and triglycerides, increasing blood pressure through RAAS activation, promoting insulin resistance, and impairing endothelial nitric oxide production.
PFAS-accelerated atherosclerosis in carotid arteries — the vessels supplying the brain — is particularly relevant to stroke risk. Carotid intima-media thickness (cIMT), a measure of early atherosclerosis and an independent predictor of stroke risk, is increased in individuals with higher PFAS blood levels in cross-sectional studies.
Epidemiological Evidence
A prospective analysis of the Atherosclerosis Risk in Communities (ARIC) study found that individuals with higher PFAS blood levels had significantly elevated stroke incidence over 25 years of follow-up. The association was strongest for PFOA and PFOS and was independent of conventional stroke risk factors, suggesting PFAS contributes to stroke risk beyond what can be explained by its effects on recognized risk factors.
Studies of communities near PFAS contamination sources have found elevated stroke mortality rates compared to unexposed reference communities. The ecologic design limits causal conclusions, but combined with the prospective cohort data, the evidence for PFAS-stroke association is sufficiently consistent to warrant clinical attention in contaminated communities.
Stroke Prevention in High-PFAS Populations
Neurologists and primary care physicians in PFAS-contaminated communities should consider that conventional cardiovascular risk calculators may underestimate stroke risk if they do not account for PFAS-related vascular burden. Modified risk stratification — treating PFAS exposure as an additional risk factor similar to a family history — may be warranted.
Stroke prevention measures that target PFAS-relevant mechanisms — antihypertensive therapy, statin use for dyslipidemia, glucose control, and antiplatelet therapy where appropriate — directly address the pathways through which PFAS increases stroke risk. These interventions work in parallel with PFAS exposure reduction through water filtration to comprehensively address modifiable cerebrovascular risk.